Krupka et al. indicated that the CD33/CD3 BiTE antibody construct AMG 330 on primary acute myeloid leukemia (AML) cell AMG 330 up-regulates immune checkpoints, PD-1 and PD-L1 on target and effector cells [43]. This evidence concerns the gene CD33 and acute myeloid leukemia.